In addition, immune checkpoint inhibitor (ICI) treatment has functioned as the standard of care for patients with extensive-stage small cell lung cancer or locally advanced/metastatic non-small cell lung cancer without EGFR/ALK alterations [13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.